Quick Answer
MoonLake Immunotherapeutics reported Earnings Per Share Diluted of $3.53 (loss) per share for the year ending 2025.
- MoonLake Immunotherapeutics showed a decrease of -86.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $2.90 (loss) per share | Q3 2021: $2.63 (loss) per share | Q1 2022: $3.17 (loss) per share | Q2 2022: $0.34 (loss) per share | Q3 2022: $0.27 (loss) per share | Q1 2023: $0.23 (loss) per share | Q2 2023: $0.23 (loss) per share | Q3 2023: $0.18 (loss) per share | Q1 2024: $0.22 (loss) per share | Q2 2024: $0.39 (loss) per share | Q3 2024: $0.56 (loss) per share | Q1 2025: $0.63 (loss) per share | Q2 2025: $0.87 (loss) per share | Q3 2025: $1.10 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), MoonLake Immunotherapeutics's Earnings Per Share Diluted has declined by 107.6%.
- Historical annual values: Fiscal year 2025: $3.53 (loss) per share | Fiscal year 2024: $1.89 (loss) per share | Fiscal year 2023: $0.73 (loss) per share | Fiscal year 2022: $1.70 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: